Protagenic Therapeutics advances PT00114 into multiple-dose phase 1 – Longevity.Technology
Protagenic Therapeutics has completed first-dose injections for all participants in the multiple-dose segment of its ongoing Phase 1 clinical trial
Scientists discover key brain aging protein
UCSF researchers demonstrate that the pro-aging effects of FTL1 can be reversed, restoring robust neural connectivity in mice. A new
Prolon Next Gen brings fasting science to the table
L-Nutra’s latest iteration of its Fasting Mimicking Diet adds ready-to-eat meals – as decades of longevity science continue to drive
Human Longevity taps precision proteomics for early detection
Preventive health provider teams up with Alamar Biosciences on proteomic biomarkers linked to chronic inflammation and neurological health. Precision medicine
Human Longevity partners with Alamar Biosciences to enhance longevity research – Longevity.Technology
Human Longevity, Inc. has announced a strategic partnership with Alamar Biosciences, Inc. to incorporate advanced proteomic testing into its precision
HCW Biologics unveils second-generation immune checkpoint inhibitor – Longevity.Technology
HCW Biologics Inc., a U.S.-based clinical-stage biopharmaceutical company, announced that it has developed a second-generation, pembrolizumab-based immune checkpoint inhibitor targeting
Serina Therapeutics gets FDA support for SER-252 registrational trial design – Longevity.Technology
Serina Therapeutics announced that feedback from the U.S. Food and Drug Administration supports advancing its investigational therapy SER-252 (POZ-apomorphine) into
Jupiter Neurosciences launches Nugevia website and opens pre-orders – Longevity.Technology
Jupiter Neurosciences has launched a new Nugevia™ e-commerce site and begun accepting pre-orders for three inaugural nutraceutical supplements, with shipments
Nanoscope unveils 3-year remain trial results for retinitis pigmentosa – Longevity.Technology
Nanoscope Therapeutics presented three-year follow-up data from its REMAIN study of RESTORE Phase 2b trial, focusing on MCO-010 (sonpiretigene isteparvovec),
Skin longevity biotech lands $20m for AI ingredient discovery
Debut targets US and Asia expansion, leveraging AI-discovered ingredients that target the hallmarks of aging in skin. Skin longevity biotech
Amylyx discontinues ORION program for AMX0035 in PSP – Longevity.Technology
Amylyx Pharmaceuticals has announced that it will discontinue the ORION program of AMX0035 for progressive supranuclear palsy (PSP), following results
What biomarkers of aging need to reach clinic
Jesse Poganik, Codirector, Biomarkers of Aging Consortium, on the hurdles and promise of bringing aging biomarkers to the clinic. The